Cadrenal Therapeutics, Inc. CVKD
We take great care to ensure that the data presented and summarized in this overview for Cadrenal Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CVKD
Top Purchases
Top Sells
About CVKD
Insider Transactions at CVKD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 10
2024
|
Quang X Pham CEO and Chairman |
SELL
Bona fide gift
|
Direct |
50,000
-1.5%
|
-
|
|
Oct 23
2023
|
Quang X Pham CEO and Chairman |
SELL
Bona fide gift
|
Direct |
85,000
-2.49%
|
-
|
|
Oct 05
2023
|
John Raymond Murphy Director |
BUY
Open market or private purchase
|
Direct |
2,669
+0.43%
|
$0
$0.69 P/Share
|
|
Oct 04
2023
|
John Raymond Murphy Director |
BUY
Open market or private purchase
|
Direct |
17,331
+2.75%
|
$0
$0.7 P/Share
|
|
Sep 05
2023
|
Quang X Pham CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
40,000
+0.58%
|
$0
$0.91 P/Share
|
|
Sep 01
2023
|
Quang X Pham CEO and Chairman |
BUY
Open market or private purchase
|
Direct |
70,000
+0.42%
|
$0
$0.91 P/Share
|
|
Mar 21
2023
|
John Raymond Murphy Director |
BUY
Open market or private purchase
|
Direct |
10,000
+1.65%
|
$10,000
$1.39 P/Share
|
|
Mar 16
2023
|
John Raymond Murphy Director |
BUY
Open market or private purchase
|
Direct |
20,000
+3.36%
|
$20,000
$1.67 P/Share
|
|
Feb 10
2023
|
Quang X Pham CEO and Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+0.75%
|
$25,000
$1.94 P/Share
|
|
Jan 24
2023
|
John Raymond Murphy Director |
BUY
Conversion of derivative security
|
Direct |
514,792
+48.13%
|
-
|
|
Jan 24
2023
|
Matthew K Szot Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+9.09%
|
-
|
|
Jan 24
2023
|
Glynn Wilson Director |
BUY
Conversion of derivative security
|
Direct |
50,000
+50.0%
|
-
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
135K
Shares
From
1
Insiders
| Bona fide gift | 135K shares |
|---|